XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has announced the filing and mailing of meeting documents for its upcoming Annual and Special Meeting of Shareholders. The management information circular is now available on the company's website, SEDAR+, and the SEC's website. The meeting is scheduled for September 12, 2024, at 10:00 am (Calgary Time) at the company's offices.
Shareholders are encouraged to review the circular and vote their shares by September 10, 2024. The Board of Directors recommends voting FOR ALL proposed items. For assistance with voting, shareholders can contact Laurel Hill Advisory Group. The company also clarified a misreported statement regarding Patrick Treanor's board attendance in 2023.
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Francoforte: ANU) ha annunciato il deposito e l'invio dei documenti per l'incontro relativo alla sua prossima Assemblea Annuale e Straordinaria degli Azionisti. Il circolare informativa della gestione è ora disponibile sul sito web della società, su SEDAR+ e sul sito della SEC. L'incontro è programmato per 12 settembre 2024, alle 10:00 (ora di Calgary) presso gli uffici della società.
Gli azionisti sono invitati a esaminare la circolare e a votare le loro azioni entro il 10 settembre 2024. Il Consiglio di Amministrazione raccomanda di votare PER TUTTI gli elementi proposti. Per assistenza con il voto, gli azionisti possono contattare Laurel Hill Advisory Group. La società ha anche chiarito una dichiarazione errata riguardante la presenza di Patrick Treanor nel consiglio nel 2023.
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) ha anunciado la presentación y envío de documentos para su próxima Junta Anual y Extraordinaria de Accionistas. El circular informativa de la administración ya está disponible en el sitio web de la empresa, en SEDAR+ y en el sitio web de la SEC. La reunión está programada para el 12 de septiembre de 2024, a las 10:00 am (hora de Calgary) en las oficinas de la empresa.
Se anima a los accionistas a revisar el circular y votar sus acciones antes del 10 de septiembre de 2024. La Junta Directiva recomienda votar A FAVOR de TODOS los puntos propuestos. Para asistencia con la votación, los accionistas pueden contactar a Laurel Hill Advisory Group. La empresa también aclaró una declaración errónea sobre la asistencia de Patrick Treanor a la junta en 2023.
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | 프랑크푸르트: ANU)는 주주를 위한 연례 및 특별 회의 관련 문서의 작성 및 발송을 발표했습니다. 관리 정보 서한은 지금 회사 웹사이트, SEDAR+, 그리고 SEC 웹사이트에서 확인할 수 있습니다. 회의는 2024년 9월 12일 오전 10:00 (캘거리 시간)에 회사 사무실에서 진행될 예정입니다.
주주들은 서한을 검토하고 2024년 9월 10일까지 그들의 주식에 투표할 것을 권장합니다. 이사회는 제안된 모든 항목에 대해 찬성투표를 할 것을 추천합니다. 투표에 대한 도움이 필요할 경우, 주주들은 Laurel Hill Advisory Group에 연락할 수 있습니다. 또한, 회사는 2023년 패트릭 트리너의 이사회 참석에 대해 잘못 보도된 내용을 명확히 했습니다.
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Francfort: ANU) a annoncé le dépôt et l'envoi des documents pour sa prochaine Assemblée Annuelle et Spéciale des Actionnaires. Le circulaire d'information de la direction est désormais disponible sur le site web de l'entreprise, sur SEDAR+ et sur le site de la SEC. La réunion est prévue pour le 12 septembre 2024 à 10h00 (heure de Calgary) dans les bureaux de l'entreprise.
Les actionnaires sont encouragés à consulter le circulaire et à voter leurs actions d'ici le 10 septembre 2024. Le Conseil d'Administration recommande de voter POUR TOUS les éléments proposés. Pour toute assistance concernant le vote, les actionnaires peuvent contacter Laurel Hill Advisory Group. L'entreprise a également clarifié une déclaration mal rapportée concernant la présence de Patrick Treanor au conseil en 2023.
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) hat die Einreichung und den Versand der Unterlagen für die bevorstehende jährliche und außerordentliche Hauptversammlung der Aktionäre angekündigt. Der Informationskreis der Geschäftsführung ist jetzt auf der Website des Unternehmens, auf SEDAR+ und auf der Website der SEC verfügbar. Die Sitzung ist für den 12. September 2024, um 10:00 Uhr (Calgary-Zeit) in den Büros des Unternehmens angesetzt.
Die Aktionäre werden ermutigt, den Kreis zu überprüfen und ihre Stimmen bis zum 10. September 2024 abzugeben. Der Vorstand empfiehlt, für alle vorgeschlagenen Punkte zu stimmen. Bei Fragen zur Abstimmung können Aktionäre die Laurel Hill Advisory Group kontaktieren. Das Unternehmen hat zudem eine fehlerhaft berichtete Aussage bezüglich der Teilnahme von Patrick Treanor im Vorstand im Jahr 2023 klargestellt.
- Timely filing and distribution of meeting documents, demonstrating transparency and compliance
- Engagement of Laurel Hill Advisory Group for shareholder assistance, potentially improving voter turnout
- None.
CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the management information circular (the “Circular”) for the annual and special meeting (the “Meeting”) of shareholders is now available on the Company’s website at https://www.xortx.com/investors/news-events/ir-calendar/detail/7671/annual-and-special-meeting-of-shareholders as well as on the Company’s SEDAR+ profile (www.sedarplus.ca) and the SEC’s website (www.sec.gov). The mailing of the Circular and related Meeting materials occurred on August 21, 2024.
XORTX will hold the Meeting on September 12, 2024, at 10:00 am (Calgary Time) at the offices of the Company at 3710 – 33rd Street NW, Calgary.
Your vote is important no matter how many shares you hold. Vote today.
Shareholders who have questions or need assistance with voting their shares should contact
XORTX’s strategic advisor and proxy solicitation agent Laurel Hill Advisory Group by telephone at
1-877-452-7184 or by email at assistance@laurelhill.com.
The Board of Directors of XORTX recommends that Shareholders
vote FOR ALL proposed items
Shareholders are encouraged to read the Circular and vote your shares as soon as possible. The deadline for voting your shares is at 10:00 am (Calgary Time) on Tuesday, September 10, 2024.
Within the Circular, XORTX provides clarification of a misreported statement - disclosure of Patrick Treanor’s board attendance in the Circular under the section Participation of Directors in Board Meetings was incorrectly reported. Patrick Treanor was not a member of the board at the time any of the seven meetings for the year 2023 took place. Therefore, his “Attendance / Number of Board Meetings” record would more accurately be disclosed as 0/0 as opposed to 0/7.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
| Allen Davidoff, CEO adavidoff@xortx.com or +1 403 455 7727 | Nick Rigopulos, Director of Communications nick@alpineequityadv.com or +1 617 901 0785 |
| Kim Golodetz, LHA Investor Relations kgolodetz@lhai.com or +1 212 838 3777 |
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
FAQ
When is XORTX Therapeutics (XRTX) holding its Annual and Special Meeting of Shareholders?
What is the voting deadline for XORTX Therapeutics (XRTX) shareholders?
Where can shareholders find the management information circular for XORTX Therapeutics (XRTX)?
What recommendation does the Board of Directors of XORTX Therapeutics (XRTX) make regarding the proposed items?
